Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Oct 18;3(10):100778.
doi: 10.1016/j.xcrm.2022.100778.

Targeting LRRK2 in Parkinson's disease

Bin Xiao  1 , Eng-King Tan  2
Affiliations
Comment

Targeting LRRK2 in Parkinson's disease

Bin Xiao et al. Cell Rep Med. .

Abstract

Jennings et al.1 reported that LRRK2 inhibitors can reduce kinase activity and improve lysosomal function with minor adverse effects in both animal models and human subjects. The findings provide proof of principle for LRRK2 inhibitor as a Parkinson's disease therapeutic option.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1
Figure 1
Success and perspective on LRRK2 inhibitor in the PD therapeutic development DNL201 reduced LRRK2 kinase activity and improved lysosomal functions in cellular and animal Parkinson’s disease models, healthy subjects, and PD patients with minimal adverse effects. Future clinical trials should explore patient selections based on LRRK2 functions. Reliable means of measuring in vivo kinase activity needs to be developed together with comprehensive assessment of clinical outcomes. CSF, cerebrospinal fluid; iPSC, induced pluripotent stem cell. Figure 1 was partially generated using templates from Servier Medical Art, which is licensed under a Creative Commons Attribution 3.0 Unported License.
See this image and copyright information in PMC

Comment on

  • Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease.
    Jennings D, Huntwork-Rodriguez S, Henry AG, Sasaki JC, Meisner R, Diaz D, Solanoy H, Wang X, Negrou E, Bondar VV, Ghosh R, Maloney MT, Propson NE, Zhu Y, Maciuca RD, Harris L, Kay A, LeWitt P, King TA, Kern D, Ellenbogen A, Goodman I, Siderowf A, Aldred J, Omidvar O, Masoud ST, Davis SS, Arguello A, Estrada AA, de Vicente J, Sweeney ZK, Astarita G, Borin MT, Wong BK, Wong H, Nguyen H, Scearce-Levie K, Ho C, Troyer MD. Jennings D, et al. Sci Transl Med. 2022 Jun 8;14(648):eabj2658. doi: 10.1126/scitranslmed.abj2658. Epub 2022 Jun 8. Sci Transl Med. 2022. PMID: 35675433

References

    1. Jennings D., Huntwork-Rodriguez S., Henry A.G., Sasaki J.C., Meisner R., Diaz D., Solanoy H., Wang X., Negrou E., Bondar V.V., et al. Preclinical and clinical evaluation of the LRRK2 inhibitor DNL201 for Parkinson's disease. Sci. Transl. Med. 2022;14:eabj2658. doi: 10.1126/scitranslmed.abj2658. - DOI - PubMed
    1. Jankovic J., Tan E.K. Parkinson's disease: etiopathogenesis and treatment. J. Neurol. Neurosurg. Psychiatry. 2020;91:795–808. doi: 10.1136/jnnp-2019-322338. - DOI - PubMed
    1. Lesage S., Durr A., Tazir M., Lohmann E., Leutenegger A.L., Janin S., Pollak P., Brice A., French Parkinson's Disease Genetics Study G. LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 2006;354:422–423. doi: 10.1056/NEJMc055540. - DOI - PubMed
    1. Xiao B., Deng X., Ng E.Y.L., Allen J.C., Jr., Lim S.Y., Ahmad-Annuar A., Tan E.K. Association of LRRK2 Haplotype with Age at Onset in Parkinson disease. JAMA Neurol. 2018;75:127. doi: 10.1001/jamaneurol.2017.3363. - DOI - PMC - PubMed
    1. Smith W.W., Pei Z., Jiang H., Dawson V.L., Dawson T.M., Ross C.A. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006;9:1231–1233. doi: 10.1038/nn1776. - DOI - PubMed

Publication types

MeSH terms

Substances